JP2020533362A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533362A5
JP2020533362A5 JP2020514968A JP2020514968A JP2020533362A5 JP 2020533362 A5 JP2020533362 A5 JP 2020533362A5 JP 2020514968 A JP2020514968 A JP 2020514968A JP 2020514968 A JP2020514968 A JP 2020514968A JP 2020533362 A5 JP2020533362 A5 JP 2020533362A5
Authority
JP
Japan
Prior art keywords
sequence
seq
variable region
multispecific antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020514968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/050931 external-priority patent/WO2019055689A1/en
Publication of JP2020533362A publication Critical patent/JP2020533362A/ja
Publication of JP2020533362A5 publication Critical patent/JP2020533362A5/ja
Pending legal-status Critical Current

Links

Images

JP2020514968A 2017-09-13 2018-09-13 エクト酵素に結合する重鎖抗体 Pending JP2020533362A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558147P 2017-09-13 2017-09-13
US62/558,147 2017-09-13
PCT/US2018/050931 WO2019055689A1 (en) 2017-09-13 2018-09-13 HEAVY CHAIN ANTIBODIES BINDING TO EXOENZYMES

Publications (2)

Publication Number Publication Date
JP2020533362A JP2020533362A (ja) 2020-11-19
JP2020533362A5 true JP2020533362A5 (enExample) 2021-11-04

Family

ID=63714117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514968A Pending JP2020533362A (ja) 2017-09-13 2018-09-13 エクト酵素に結合する重鎖抗体

Country Status (13)

Country Link
US (1) US20200207867A1 (enExample)
EP (1) EP3681908A1 (enExample)
JP (1) JP2020533362A (enExample)
KR (1) KR20200044094A (enExample)
CN (1) CN111133007A (enExample)
AU (1) AU2018331421A1 (enExample)
BR (1) BR112020004846A2 (enExample)
CA (1) CA3075399A1 (enExample)
IL (1) IL273235A (enExample)
MX (1) MX2020002802A (enExample)
RU (1) RU2020112490A (enExample)
SG (1) SG11202002093TA (enExample)
WO (1) WO2019055689A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322083A (en) 2016-08-24 2025-09-01 Teneobio Inc Non-human transgenic animals that produce modified heavy chain antibodies only
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
CN111683966B (zh) 2017-12-22 2023-07-11 特尼奥生物股份有限公司 与cd22结合的重链抗体
WO2020206330A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CN115023441A (zh) * 2019-12-18 2022-09-06 特诺福尔股份有限公司 与cd38结合的重链抗体
CA3171906A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
KR101151957B1 (ko) 2004-07-22 2012-06-01 로저 킹돈 크레이그 결합 분자
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
AU2006323415A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
CA2647524C (en) 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PL2602323T3 (pl) 2007-06-01 2018-06-29 Open Monoclonal Technology, Inc. Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
KR20130009760A (ko) * 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US20150118251A1 (en) * 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
JP2016538275A (ja) * 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
EP3699195A3 (en) * 2014-03-28 2020-11-04 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
JP6180663B2 (ja) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
EA201792546A1 (ru) * 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
AU2016352676A1 (en) * 2015-11-10 2018-05-31 University Medical Center Hamburg - Eppendorf ANTIGEN-binding polypeptides directed against CD38

Similar Documents

Publication Publication Date Title
JP2020533362A5 (enExample)
JP2020519600A5 (enExample)
JP2021527431A5 (enExample)
JP2019110906A5 (enExample)
JP2014158469A5 (enExample)
JP2021511811A5 (enExample)
JP2018519263A5 (enExample)
JP2021525248A5 (enExample)
JP2017528462A5 (enExample)
JP2011046732A5 (enExample)
JP2015508280A5 (enExample)
JP2017501157A5 (enExample)
JP2018506277A5 (enExample)
JP2017515815A5 (enExample)
JP2015532292A5 (enExample)
JP2014530215A5 (enExample)
IL265541B2 (en) Bispecific antibodies and compounds containing them for the treatment of cancer
JP2018513149A5 (enExample)
JP2018500014A5 (enExample)
JP2018507220A5 (enExample)
JP2021510736A5 (enExample)
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2015520758A5 (enExample)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
JP2017529838A5 (enExample)